RCC Rapid Fire Rounds (10-12 pin pointed clinical questions from the community).
RCC Content Hub
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC).
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
• X/Twitter: https://x.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Join us as we dived into topics including:
• The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan
• Treatment strategies for oligometastatic disease and the use of radiation
• Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and the implications of treatment breaks for patients on immuno-oncology (IO)–tyrosine kinase inhibitor (TKI) regimens
• The evolving landscape of metastatic RCC, including the comparison of IO-IO versus IO-TKI combinations and the importance of patient-centered decision-making
• The challenges and considerations in treating non–clear cell RCC, including the latest data on treatment options
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.
Don't forget to like, subscribe, and hit the notification bell for more episodes!
#RCC, #KidneyCancer, #AdjuvantTherapy, #IO-TKI, #OncologyBrothers